WallStSmart

Aveanna Healthcare Holdings Inc (AVAH)vsMerck & Company Inc (MRK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 2572% more annual revenue ($65.01B vs $2.43B). MRK leads profitability with a 28.1% profit margin vs 9.3%. AVAH trades at a lower P/E of 6.2x. AVAH earns a higher WallStSmart Score of 62/100 (C+).

AVAH

Buy

62

out of 100

Grade: C+

Growth: 8.7Profit: 7.5Value: 8.3Quality: 5.0

MRK

Buy

59

out of 100

Grade: C

Growth: 4.0Profit: 9.5Value: 4.7Quality: 4.8
Piotroski: 3/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AVAHUndervalued (+57.0%)

Margin of Safety

+57.0%

Fair Value

$18.54

Current Price

$6.55

$11.99 discount

UndervaluedFair: $18.54Overvalued
MRKOvervalued (-13.2%)

Margin of Safety

-13.2%

Fair Value

$96.48

Current Price

$109.18

$12.70 premium

UndervaluedFair: $96.48Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AVAH4 strengths · Avg: 9.5/10
P/E RatioValuation
6.2x10/10

Attractively priced relative to earnings

Return on EquityProfitability
61.6%10/10

Every $100 of equity generates 62 in profit

EPS GrowthGrowth
465.2%10/10

Earnings expanding 465.2% YoY

Revenue GrowthGrowth
27.4%8/10

Revenue surging 27.4% year-over-year

MRK6 strengths · Avg: 9.2/10
Market CapQuality
$274.03B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
36.9%10/10

Every $100 of equity generates 37 in profit

Operating MarginProfitability
32.8%10/10

Strong operational efficiency at 32.8%

Profit MarginProfitability
28.1%9/10

Keeps 28 of every $100 in revenue as profit

P/E RatioValuation
15.2x8/10

Attractively priced relative to earnings

Free Cash FlowQuality
$1.82B8/10

Generating 1.8B in free cash flow

Areas to Watch

AVAH1 concerns · Avg: 3.0/10
Market CapQuality
$1.42B3/10

Smaller company, higher risk/reward

MRK3 concerns · Avg: 2.3/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
3.362/10

Expensive relative to growth rate

EPS GrowthGrowth
-19.3%2/10

Earnings declined 19.3%

Comparative Analysis Report

WallStSmart Research

Bull Case : AVAH

The strongest argument for AVAH centers on P/E Ratio, Return on Equity, EPS Growth. Revenue growth of 27.4% demonstrates continued momentum.

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 28.1% and operating margin at 32.8%.

Bear Case : AVAH

The primary concerns for AVAH are Market Cap.

Bear Case : MRK

The primary concerns for MRK are Piotroski F-Score, PEG Ratio, EPS Growth.

Key Dynamics to Monitor

AVAH profiles as a growth stock while MRK is a value play — different risk/reward profiles.

AVAH carries more volatility with a beta of 2.09 — expect wider price swings.

AVAH is growing revenue faster at 27.4% — sustainability is the question.

MRK generates stronger free cash flow (1.8B), providing more financial flexibility.

Bottom Line

AVAH scores higher overall (62/100 vs 59/100) and 27.4% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Aveanna Healthcare Holdings Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Aveanna Healthcare Holdings Inc., a diversified home care platform company, offers private duty nursing (PDN) services, adult home health and palliative care, pediatric home therapy, and enteral nutrition services in the United States. The company is headquartered in Atlanta, Georgia.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Want to dig deeper into these stocks?